Environmental Chemical Contribution to the Modulation of Bile Acid Homeostasis and Farnesoid X Receptor Signaling

被引:7
|
作者
Taylor, Rulaiha E. [1 ]
Bhattacharya, Anisha [1 ]
Guo, Grace L. [1 ,2 ,3 ,4 ]
机构
[1] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ USA
[2] Rutgers State Univ, Environm & Occupat Hlth Sci Inst, Piscataway, NJ USA
[3] Rutgers State Univ, Rutgers Ctr Lipid Res, Piscataway, NJ USA
[4] VA New Jersey Hlth Care Syst, Vet Adm Med Ctr, E Orange, NJ USA
基金
美国国家卫生研究院;
关键词
ARYL-HYDROCARBON RECEPTOR; FATTY LIVER-DISEASE; BREAST-CANCER RISK; NONALCOHOLIC STEATOHEPATITIS; ORGANOCHLORINE PESTICIDES; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; PERFLUOROALKYL SULFONATES; ENDOGENOUS BIOMARKERS; EXPRESSION CLONING; OBETICHOLIC ACID;
D O I
10.1124/dmd.121.000388
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Maintaining bile acid (BA) homeostasis is important and regulated by BA activated receptors and signaling pathways. Farnesoid X receptor (FXR) and its regulated target networks in both the liver and the intestines are critical in suppressing BA synthesis and promoting BA transport and enterohepatic circulation. In addition, FXR is critical in regulating lipid metabolism and reducing inflammation, processes critical in the development of cholestasis and fatty liver diseases. BAs are modulated by, but also control, gut microflora. Environmental chemical exposure could affect liver disease development. However, the effects and the mechanisms by which environmental chemicals interact with FXR to affect BA homeostasis are only emerging. In this minireview, our focus is to provide evidence from reports that determine the effects of environmental or therapeutic exposure on altering homeostasis and functions of BAs and FXR. Understanding these effects will help to determine liver disease pathogenesis and provide better prevention and treatment in the future. SIGNIFICANCE STATEMENT Environmental chemical exposure significantly contributes to the development of cholestasis and nonalcoholic steatohepatitis (NASH). The impact of exposures on bile acid (BA) signaling and Farnesoid X receptor-mediated gut-liver crosstalk is emerging. However, there is still a huge gap in understanding how these chemicals contribute to the dysregulation of BA homeostasis and how this dysregulation may promote NASH development.
引用
收藏
页码:456 / 467
页数:12
相关论文
共 50 条
  • [31] Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation
    Chiang, John Y. L.
    Pathak, Preeti
    Liu, Hailiang
    Donepudi, Ajay
    Ferrell, Jessica
    Boehme, Shannon
    DIGESTIVE DISEASES, 2017, 35 (03) : 241 - 245
  • [32] Multi-model in silico characterization of 3-benzamidobenzoic acid derivatives as partial agonists of Farnesoid X receptor in the management of NAFLD
    Mitra, Soumya
    Halder, Amit Kumar
    Ghosh, Nilanjan
    Mandal, Subhash C.
    Cordeiro, M. Natalia D. S.
    COMPUTERS IN BIOLOGY AND MEDICINE, 2023, 157
  • [33] Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome
    Pereira-Fantini, Prue M.
    Lapthorne, Susan
    Gahan, Cormac G. M.
    Joyce, Susan A.
    Charles, Jenny
    Fuller, Peter J.
    Bines, Julie E.
    CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 2017, 4 (01): : 65 - 74
  • [34] Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice
    Martin, Ina V.
    Schmitt, Johannes
    Minkenberg, Alexander
    Mertens, Joachim C.
    Stieger, Bruno
    Mullhaupt, Beat
    Geier, Andreas
    BIOLOGICAL CHEMISTRY, 2010, 391 (12) : 1441 - 1449
  • [35] Farnesoid X Receptor Regulated Sepsis-Induced Abnormal Bile Acid Metabolism via the Fibroblast Growth Factor 15/Fibroblast Growth Factor Receptor 4 Pathway
    Zhou, Ziyang
    Xu, Dan
    Huang, Liou
    Cui, Yuhui
    Chen, Hui
    Tang, Jianguo
    IMMUNITY INFLAMMATION AND DISEASE, 2025, 13 (04)
  • [36] Modulation of immune responses by bile acid receptor agonists in myasthenia gravis
    Howlett-Prieto, Quentin
    Langer, Collin
    Rezania, Kourosh
    Soliven, Betty
    JOURNAL OF NEUROIMMUNOLOGY, 2020, 349
  • [37] Farnesoid X receptor signaling activates the hepatic X-box binding protein 1 pathway in vitro and in mice
    Liu, Xiaoying
    Guo, Grace L.
    Kong, Bo
    Hilburn, David B.
    Hubchak, Susan C.
    Park, Seong
    LeCuyer, Brian
    Hsieh, Antony
    Wang, Li
    Fang, Deyu
    Green, Richard M.
    HEPATOLOGY, 2018, 68 (01) : 304 - 316
  • [38] Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling
    Meadows, Vik
    Kennedy, Lindsey
    Ekser, Burcin
    Kyritsi, Konstantina
    Kundu, Debjyoti
    Zhou, Tianhao
    Chen, Lixian
    Pham, Linh
    Wu, Nan
    Demieville, Jennifer
    Hargrove, Laura
    Glaser, Shannon
    Alpini, Gianfranco
    Francis, Heather
    HEPATOLOGY, 2021, 74 (05) : 2684 - 2698
  • [39] The Status of Bile Acids and Farnesoid X Receptor in Brain and Liver of Rats with Thioacetamide-Induced Acute Liver Failure
    Czarnecka, Anna Maria
    Milewski, Krzysztof
    Albrecht, Jan
    Zielinska, Magdalena
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (20) : 1 - 12
  • [40] Synthesis of obeticholic acid, a farnesoid X receptor agonist, and its major metabolites labeled with deuterium
    Gai, Kuo
    Huang, Yu
    Liu, Baomin
    Zhang, Yinsheng
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2018, 61 (10) : 799 - 804